“Bio-Rad is pleased to partner with Diagenode, a key player in the epigenetics market."
DENVILLE, N.J. and HERCULES, Calif. (PRWEB) November 20, 2019
Diagenode, Inc., a leading global provider of solutions for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring Bio-Rad’s Droplet Digital technology, to help advance epigenomics research.
Diagenode’s scATAC-Seq Services leverage the combined capabilities of Bio-Rad’s Droplet Digital technology and Diagenode’s epigenetics expertise to help researchers gain a greater understanding of the epigenome, the multitude of chemical compounds and proteins that give instructions to the genome. The scATAC-Seq Services utilize Bio Rad’s ddSEQ Single-Cell Isolator to encapsulate thousands of cell nuclei or whole cells into nanoliter-sized droplets and offer robust precision and quantification of data.
scATAC-Seq solutions enable the genome-wide study of accessible chromatin that represents regulatory regions at the single-cell level. In contrast to standard bulk ATAC-Seq, scATAC-Seq provides a way for thousands of cells to be assessed in parallel to better parse heterogeneous populations.
“We are excited to offer scientists the combination of Diagenode’s epigenetic service excellence and Bio-Rad’s industry-leading scATAC-Seq technology,” said Joe Bertelsen, Business Unit Manager at Diagenode. “This collaboration demonstrates our continued commitment to enabling advances in epigenomics research.”
“Bio-Rad is pleased to partner with Diagenode, a key player in the epigenetics market,” said Kris Simonyi, Global Marketing Manager at Bio-Rad’s Digital Biology Group. “By working together to combine our expertise, we look forward to accelerating epigenetics and gene regulation research at the single-cell level.”
To learn more about Diagenode’s Single-Cell ATAC-Seq Services, please visit: https://www.diagenode.com/p/single-cell-atac-seq-service
BIO-RAD, DDSEQ, and DROPLET DIGITAL SEQ are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit http://www.bio-rad.com.
About Diagenode, Inc.
Diagenode is a leading provider of complete solutions for epigenetic research and epigenomics services. The company has developed a comprehensive approach to gain new insights into epigenetic studies, offering innovative shearing and automation instruments, reagent kits, and high-quality antibodies to streamline DNA methylation, noncoding RNA-seq, ChIP, and ChIP-seq workflows. The company’s latest innovations include a unique full automation system, a Reduced Representation Bisulfite Sequencing (RRBS) Kit providing eight times more coverage than standard technologies, ChIPmentation and ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.